Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.

ABSTRACT:

Importance

Prurigo nodularis (PN) is a debilitating skin disease characterized by intense pruritus and hyperkeratotic skin nodules. Nemolizumab, a monoclonal antibody targeting interleukin 31 receptor α, is a promising novel therapy for the treatment of moderate to severe PN. The biological mechanisms by which nemolizumab promotes improvement of itch and skin lesions in PN are unknown.

Objective

To characterize changes in plasma protein biomarkers associated with clinical response to nemolizumab in patients with PN.

Design, setting, and participants

This multicenter cohort study included patients recruited from Austria, France, Germany, Poland, and the US from a phase 2 clinical trial. Adults diagnosed with moderate to severe PN with severe pruritus for at least 6 mon

SUBMITTER: Deng J 

PROVIDER: S-EPMC10413221 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature